

Federica Cavallo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9369855/federica-cavallo-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

7,191
citations

41
h-index

79
g-index

181
ext. papers

8,057
ext. citations

7.2
avg. IF

5.34
L-index

#	Paper	IF	Citations
164	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.. <i>Frontiers in Veterinary Science</i> , 2022 , 9, 803093	3.1	0
163	Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022 , 12, 877384	5.3	
162	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. 2022 , 10,		1
161	Canine Melanoma and Osteosarcoma Immunotherapy by Means of In Vivo DNA Electroporation 2021 , 277-304		
160	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2021 , 11, 610303	5.3	22
159	Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases. <i>Veterinary and Comparative Oncology</i> , 2021 , 19, 651-660	2.5	5
158	Targeting the Extracellular HSP90 Co-Chaperone Morgana Inhibits Cancer Cell Migration and Promotes Anticancer Immunity. <i>Cancer Research</i> , 2021 , 81, 4794-4807	10.1	2
157	Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential. <i>British Journal of Cancer</i> , 2021 , 124, 207-216	8.7	14
156	Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies. <i>Cells</i> , 2021 , 10,	7.9	6
155	Evaluation of prognostic impact of pre-treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant CSPG4-antigen electrovaccination: an explorative study. <i>Veterinary and Comparative Oncology</i> , 2021 , 19, 353-361	2.5	3
154	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
153	The Amot/integrin protein complex transmits mechanical forces required for vascular expansion. <i>Cell Reports</i> , 2021 , 36, 109616	10.6	1
152	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. <i>MABs</i> , 2021 , 13, 1913791	6.6	6
151	Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. <i>Viruses</i> , 2020 , 12,	6.2	19
150	Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer. <i>Cancer Immunology Research</i> , 2020 , 8, 1039-1053	12.5	13
149	Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression. <i>International Journal of Biological Sciences</i> , 2020 , 16, 1238-1251	11.2	13
148	Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9

147	Breast cancer stem cell antigens as targets for immunotherapy. <i>Seminars in Immunology</i> , 2020 , 47, 101386-7	6.7	23
146	Cancer stem cell antigens as targets for new combined anti-cancer therapies. <i>International Journal of Biochemistry and Cell Biology</i> , 2020 , 129, 105861	5.6	4
145	Liver-Specific siRNA-Mediated Stat3 or C3 Knockdown Improves the Outcome of Experimental Autoimmune Myocarditis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020 , 18, 62-72	6.4	1
144	Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
143	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas . <i>Vaccines</i> , 2020 , 8,	5.3	1
142	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919855491	5.4	10
141	Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1839-1853	7.4	20
140	Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. <i>Progress in Molecular Biology and Translational Science</i> , 2019 , 164, 119-188	4	22
139	Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 131-141	7.4	24
138	In Vitro and In Vivo and In Silico Investigation of the Anticancer Effectiveness of Oxygen-Loaded Chitosan-Shelled Nanodroplets as Potential Drug Vector. <i>Pharmaceutical Research</i> , 2018 , 35, 75	4.5	10
137	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	20
136	Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 1417-1425	12.5	17
135	A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer. <i>Oncotmunology</i> , 2018 , 7, e1408746	7.2	32
134	Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. <i>Oncotmunology</i> , 2018 , 7, e1494108	7.2	16
133	Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. <i>Veterinary and Comparative Oncology</i> , 2017 , 15, 996-1013	2.5	31
132	RNAs competing for microRNAs mutually influence their fluctuations in a highly non-linear microRNA-dependent manner in single cells. <i>Genome Biology</i> , 2017 , 18, 37	18.3	28
131	NK cells control breast cancer and related cancer stem cell hematological spread. <i>Oncotmunology</i> , 2017 , 6, e1284718	7.2	33
130	The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. <i>Nature Communications</i> , 2017 , 8, 14797	17.4	12

129	CSPG4: a prototype oncoantigen for translational immunotherapy studies. <i>Journal of Translational Medicine</i> , 2017 , 15, 151	8.5	31
128	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. <i>Current Topics in Microbiology and Immunology</i> , 2017 , 405, 99-122	3.3	10
127	The IKK/NF- κ B signaling pathway requires Morgana to drive breast cancer metastasis. <i>Nature Communications</i> , 2017 , 8, 1636	17.4	59
126	Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. <i>Vaccines</i> , 2017 , 5,	5.3	4
125	In vivo evaluation of tumour acidosis for assessing the early metabolic response and onset of resistance to dichloroacetate by using magnetic resonance pH imaging. <i>International Journal of Oncology</i> , 2017 , 51, 498-506	4.4	40
124	Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2 mammary cancer. <i>Oncolmmunology</i> , 2016 , 5, e1082705	7.2	6
123	The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2(+) mammary cancer. <i>Plant Biotechnology Journal</i> , 2016 , 14, 153-9	11.6	10
122	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2016 , 5, e1253653	7.2	18
121	Angiomotin like-1 is a novel component of the N-cadherin complex affecting endothelial/pericyte interaction in normal and tumor angiogenesis. <i>Scientific Reports</i> , 2016 , 6, 30622	4.9	15
120	A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer. <i>Oncolmmunology</i> , 2016 , 5, e1166323	7.2	16
119	Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. <i>Cancer Research</i> , 2016 , 76, 62-72	10.1	62
118	L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. <i>Oncotarget</i> , 2016 , 7, 66713-66727	3.3	46
117	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. <i>Oncotarget</i> , 2016 , 7, 33081-95	3.3	10
116	Protection of mice against the highly pathogenic VV by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity. <i>Antiviral Research</i> , 2016 , 134, 182-191	10.8	2
115	Preclinical pharmacokinetics comparison between resveratrol 2-hydroxypropyl- β -cyclodextrin complex and resveratrol suspension after oral administration. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2016 , 86, 263-271	1.7	11
114	Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging. <i>International Journal of Cancer</i> , 2016 , 139, 404-13	7.5	7
113	Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. <i>Nanoscale</i> , 2015 , 7, 6527-33	7.7	55
112	Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. <i>Magnetic Resonance Imaging</i> , 2015 , 33, 725-36	3.3	26

111	Antitumor immunization of mothers delays tumor development in cancer-prone offspring. <i>Oncolimmunology</i> , 2015 , 4, e1005500	7.2	9
110	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015 , 3, 1333-1343	12.5	25
109	Novel insights into Notum and glypicans regulation in colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 41237-57	3.3	37
108	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015 , 3, 467-89	5.3	23
107	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Oncolimmunology</i> , 2015 , 4, e998538	7.2	101
106	The importance of comparative oncology in translational medicine. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 137-48	7.4	24
105	2H,3H-decafluoropentane-based nanodroplets: new perspectives for oxygen delivery to hypoxic cutaneous tissues. <i>PLoS ONE</i> , 2015 , 10, e0119769	3.7	31
104	Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies. <i>Leukemia</i> , 2014 , 28, 941-4	10.7	14
103	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014 , 16, R10	8.3	25
102	Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. <i>Clinical Cancer Research</i> , 2014 , 20, 2910-21	12.9	17
101	Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4. <i>FASEB Journal</i> , 2014 , 28, 416-29	0.9	25
100	Ultrasound-activated decafluoropentane-cored and chitosan-shelled nanodroplets for oxygen delivery to hypoxic cutaneous tissues. <i>RSC Advances</i> , 2014 , 4, 38433-38441	3.7	34
99	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. <i>BMC Genomics</i> , 2014 , 15 Suppl 3, S1	4.5	17
98	Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. <i>Journal of Translational Medicine</i> , 2014 , 12, 122	8.5	13
97	DNA vaccination against membrane-bound Kit ligand: a new approach to inhibiting tumour growth and angiogenesis. <i>European Journal of Cancer</i> , 2014 , 50, 234-46	7.5	6
96	A mathematical-biological joint effort to investigate the tumor-initiating ability of Cancer Stem Cells. <i>PLoS ONE</i> , 2014 , 9, e106193	3.7	11
95	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
94	Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth. <i>Oncolimmunology</i> , 2014 , 3, e27259	7.2	

93	Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice. <i>BioMed Research International</i> , 2014 , 2014, 534969	3	20
92	Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 2026-31	8.9	11
91	Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice. <i>Journal of Immunology</i> , 2014 , 192, 5434-41	5.3	14
90	Xenogene vaccination in the therapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1427-42	5.4	14
89	CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. <i>Clinical Cancer Research</i> , 2014 , 20, 3753-62	12.9	51
88	Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo 2014 ,		2
87	State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?. <i>BMC Bioinformatics</i> , 2013 , 14 Suppl 7, S2	3.6	54
86	Multi-level model for the investigation of oncoantigen-driven vaccination effect. <i>BMC Bioinformatics</i> , 2013 , 14 Suppl 6, S11	3.6	11
85	The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. <i>FASEB Journal</i> , 2013 , 27, 4731-44	0.9	62
84	Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. <i>Gastroenterology</i> , 2013 , 144, 1098-106	13.3	74
83	Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding $\alpha\beta$ integrins. <i>Contrast Media and Molecular Imaging</i> , 2013 , 8, 350-60	3.2	9
82	miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. <i>American Journal of Pathology</i> , 2013 , 182, 2058-70	5.8	46
81	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013 , 12, 1449-63	5.2	9
80	State-of-the-art fusion-finder algorithms sensitivity and specificity. <i>BioMed Research International</i> , 2013 , 2013, 340620	3	69
79	Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. <i>Frontiers in Oncology</i> , 2013 , 3, 122	5.3	14
78	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. <i>Onc Immunology</i> , 2013 , 2, e26137	7.2	21
77	ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult mice. <i>PLoS ONE</i> , 2013 , 8, e56282	3.7	19
76	IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1473-84	7.4	4

75	A vaccine targeting angiominin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. <i>Angiogenesis</i> , 2012 , 15, 305-16	10.6	33
74	DNA vaccination against oncoantigens: A promise. <i>Oncolmunology</i> , 2012 , 1, 316-325	7.2	30
73	Digging in the RNA-seq Garbage: Evaluating the Characteristics of Unmapped RNA-seq Reads in Normal Tissues 2012 ,		1
72	A pipeline to detect antibody-targetable cancer stem cell proteins.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13527-e13527	2.2	
71	Vaccines and other immunological approaches for cancer immunoprevention. <i>Current Drug Targets</i> , 2011 , 12, 1957-73	3	28
70	Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. <i>Veterinary Journal</i> , 2011 , 190, e26-e30	2.5	30
69	Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. <i>Biochemical Pharmacology</i> , 2011 , 82, 1079-89	6	9
68	A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions. <i>Archives of Virology</i> , 2011 , 156, 587-95	2.6	24
67	2011: the immune hallmarks of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 319-26	7.4	260
66	A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. <i>Cancer Prevention Research</i> , 2011 , 4, 994-1001	3.2	5
65	Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. <i>Cancers</i> , 2011 , 3, 3225-41	6.6	16
64	Oncoantigens for an immune prevention of cancer. <i>American Journal of Cancer Research</i> , 2011 , 1, 255-264	4.4	4
63	Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. <i>Cancer Research</i> , 2010 , 70, 2558-67	10.1	116
62	ErbB2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. <i>Journal of Immunology</i> , 2010 , 184, 6124-32	5.3	24
61	Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. <i>Cancer Research</i> , 2010 , 70, 7431-41	10.1	21
60	Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. <i>Journal of Immunology</i> , 2010 , 184, 4170-7	5.3	17
59	A better immune reaction to ErbB-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. <i>Cancer Research</i> , 2010 , 70, 2604-12	10.1	44
58	Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. <i>Molecular Carcinogenesis</i> , 2010 , 49, 114-20	5	26

57	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 14, 2803-15	5.6	201
56	Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. <i>International Journal of Cancer</i> , 2009 , 124, 150-6	7.5	23
55	DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. <i>Cancer Gene Therapy</i> , 2008 , 15, 108-14	5.4	27
54	Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. <i>Neoplasia</i> , 2008 , 10, 1433-43	6.4	65
53	DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 6933-43	12.9	23
52	Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. <i>Human Gene Therapy</i> , 2008 , 19, 229-40	4.8	18
51	Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. <i>Cancer Research</i> , 2008 , 68, 7530-40	10.1	30
50	ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. <i>Current Protocols in Immunology</i> , 2008 , Chapter 20, Unit 20.9.1-20.9-10	4	37
49	Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. <i>Current Cancer Drug Targets</i> , 2008 , 8, 230-42	2.8	13
48	Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1685-94	7.4	10
47	Are oncoantigens suitable targets for anti-tumour therapy?. <i>Nature Reviews Cancer</i> , 2007 , 7, 707-13	31.3	50
46	p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. <i>EMBO Journal</i> , 2007 , 26, 2843-55	13	65
45	Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. <i>Cancer Research</i> , 2007 , 67, 6425-32	10.1	33
44	Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. <i>Breast Cancer Research</i> , 2007 , 9, 211	8.3	31
43	Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. <i>Journal of Immunology</i> , 2006 , 177, 7626-33	5.3	69
42	Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. <i>Cancer Research</i> , 2006 , 66, 7734-40	10.1	71
41	A DNA vaccine targeting angiogenin inhibits angiogenesis and suppresses tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 9208-13	11.5	66
40	Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. <i>Journal of Immunology</i> , 2006 , 176, 7695-703	5.3	19

39	p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. <i>Cancer Research</i> , 2006 , 66, 4672-80	10.1	112
38	Vaccination for treatment and prevention of cancer in animal models. <i>Advances in Immunology</i> , 2006 , 90, 175-213	5.6	70
37	Vaccines for tumour prevention. <i>Nature Reviews Cancer</i> , 2006 , 6, 204-16	31.3	256
36	Cancer immunoprevention. <i>Future Oncology</i> , 2005 , 1, 57-66	3.6	42
35	Immunotherapy and immunoprevention of cancer: where do we stand?. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 717-26	5.4	5
34	Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. <i>American Journal of Pathology</i> , 2005 , 166, 1205-16	5.8	41
33	The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. <i>Vaccine</i> , 2005 , 23, 3280-7	4.1	16
32	Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas. <i>British Journal of Cancer</i> , 2005 , 93, 1250-6	8.7	5
31	An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. <i>BMC Bioinformatics</i> , 2005 , 6 Suppl 4, S7	3.6	25
30	Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. <i>International Journal of Cancer</i> , 2005 , 113, 67-77	7.5	46
29	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 599-610	7.4	12
28	Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. <i>Clinical Cancer Research</i> , 2005 , 11, 1941-52	12.9	58
27	Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. <i>Cancer Research</i> , 2005 , 65, 1071-8	10.1	33
26	Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. <i>Cancer Research</i> , 2004 , 64, 2858-64	10.1	137
25	Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. <i>Cancer Research</i> , 2004 , 64, 4001-9	10.1	79
24	Toward a Long-Lasting Immune Prevention of HER2 Mammary Carcinomas: Directions from Transgenic Mice. <i>Cell Cycle</i> , 2004 , 3, 702-704	4.7	6
23	Immunological inhibition of carcinogenesis. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 204-16	7.4	28
22	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. <i>Journal of Clinical Investigation</i> , 2004 , 113, 709-17	15.9	58

21	Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice. <i>Cell Cycle</i> , 2004 , 3, 704-6	4.7	4
20	Immunological prevention of spontaneous tumors: a new prospect?. <i>Immunology Letters</i> , 2002 , 80, 75-9	4.1	15
19	IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. <i>Journal of Immunology</i> , 2001 , 166, 3890-9	5.3	132
18	Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. <i>Journal of Experimental Medicine</i> , 2001 , 194, 1195-205	16.6	203
17	Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. <i>British Journal of Cancer</i> , 1999 , 79, 770-9	8.7	13
16	Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. <i>Journal of Experimental Medicine</i> , 1998 , 188, 589-96	16.6	252
15	Cytokines and Tumor Immunogenicity 1998 , 231-247		1
14	Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1049-58	9.7	151
13	Constitutive expression of lymphoma-associated NFkB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. <i>Oncogene</i> , 1997 , 14, 1805-10	9.2	41
12	Cytokines, tumour-cell death and immunogenicity: a question of choice. <i>Trends in Immunology</i> , 1997 , 18, 32-6		149
11	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. <i>European Journal of Immunology</i> , 1996 , 26, 1851-9	6.1	46
10	Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-gamma in the same cell: efficient MHC expression and inhibition of tumor and metastasis growth. <i>Human Gene Therapy</i> , 1995 , 6, 743-52	4.8	22
9	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. <i>European Journal of Immunology</i> , 1995 , 25, 1154-62	6.1	106
8	Systemic effects of cytokines released by gene-transduced tumor cells: marked hyperplasia induced in small bowel by gamma-interferon transfectants through host lymphocytes. <i>International Journal of Cancer</i> , 1995 , 61, 425-30	7.5	12
7	Genotypic, phenotypic and biological characterization of a novel human lung adenocarcinoma cell line (LC 89). <i>Oncology</i> , 1994 , 51, 220-3	3.6	4
6	Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. <i>Journal of Immunotherapy</i> , 1993 , 14, 253-7	5	22
5	Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. <i>International Journal of Cancer</i> , 1993 , 55, 320-9	7.5	81
4	Tumor Immunogenicity Induced by the Local Occurrence of IL-2 1993 , 31-37		

- 3 Strategies for cytokine utilisation in tumor therapy. *Medical Oncology and Tumor Pharmacotherapy*, **1993**, 10, 53-9 3
- 2 From exogenous cytokines to gene therapy: cytokine activated tumor inhibition. *Pharmacological Research*, **1992**, 26 Suppl 2, 48-9 10.2
- 1 A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. *Cell*, **1992**, 70, 93-104 56.2 1271